Maternal immune activation remodeling of offspring glycosaminoglycan sulfation patterns during neurodevelopment
Project Number3DP2AI171150-02S1
Contact PI/Project LeaderALONGE, KIMBERLY MICHELE
Awardee OrganizationUNIVERSITY OF WASHINGTON
Description
Abstract Text
ABSTRACT
Maternal immune activation (MIA) during prenatal or postnatal development significantly increases the risk for
offspring neurodevelopmental disorders (NDDs) later in life. Growing evidence suggest that regardless of the
MIA stimuli (infectious or environmental), offspring exhibit an enhanced risk for lifelong neuropathology defects
ranging from reduced brain volume to alterations in neurocircuit organization. The brain extracellular matrix-
containing chondroitin and dermatan sulfate-glycosaminoglycans (CS/DS-GAGs) are key regulators of brain
development and can be biochemically altered by neuroimmune responses. Defects in CS/DS-GAG abundance
and/or sulfation patterning (4S (CS-A), 2S4S (CS-B/DS), 6S (CS-C), 2S6S (CS-D), 4S6S (CS-E), 0S (CS-O))
result in the manifestation of similar neuropsychiatric behaviors as reported in offspring affected by MIA, but
whether and how MIA affects offspring brain matrix is unknown. By employing a novel laser capture
microdissection coupled mass spectrometry methodology (LMD-LC-MS/MS), our Preliminary Data provide the
first evidence for inter- and intra-regional differences in CS/DS-GAG sulfation pattern differences throughout the
developing mouse and non-human primate (NHP) brain. Specifically, the hippocampus exhibits a significant
increase in both developmental 6S (CS-C) and 2S6S (CS-D) isomers compared to the cortex, implying that the
hippocampus remains developmentally plastic long after the maturation of adjacent regions. Moreover, we show
that infectious Zika virus MIA during gestation in NHPs decreases the abundance of the developmental 2S6S
(CS-D) axonal growth factor attractant isomer in the hippocampus, suggesting stunted neurocircuit formation
after infectious MIA, while the non-infectious maternal high fat diet (mHFD) MIA during lactation in mice
decreases the abundance of the developmental 6S (CS-C) plasticity isomer in the hippocampus, suggested
accelerated early maturation of hippocampal neurocircuits in response to non-infectious MIA. The implication
that both infectious and non-infectious MIA insults influence the spatiotemporal regulation of brain CS/DS-GAG
sulfation patterns fits a global interconnecting theory linking a range of MIA insults with changes in offspring brain
neurodevelopment through re-coding of CS/DS-GAGs. From these results, we propose to 1) determine how MIA
exposure affects spatiotemporal expression of offspring CS/DS-GAGs and link these changes to NDDs later in
life, 2) mechanistically investigate how these MIA-induced changes in offspring CS/DS-GAGs influence glycan-
protein interactions involved in neurodevelopment, and 3) engineer a state-of-the-art nanopore sequencing
technology capable of single-molecule sequencing of biological CS/DS-GAGs to discover glycan-protein binding
elements. This multidisciplinary proposal has important translational potential to clarify how MIA exposure leads
to neuropsychiatric illness through changes in CS/DS-GAG sulfation patterning during childhood
neurodevelopment and provides valuable targets in the prevention and treatment of mental health diseases.
Public Health Relevance Statement
Maternal immune activation (MIA) is a primer for long-term neuropsychiatric consequences in offspring, although
the exact mechanisms underlying offspring neurodevelopmental defects resulting from these maternal immune
insults are unknown. Here, we provide evidence that MIA-induced changes in the developing offspring’s
extracellular chondroitin and dermatan sulfate glycosaminoglycan (CS/DS-GAG) sulfation patterning, which are
key regulator of axonal guidance and synaptogenesis during neurodevelopment, may result in developmental
defects that predispose the offspring to mental health disorders in the adult, and studies outlined within this
proposal aim to further investigate this possibility.
National Institute of Allergy and Infectious Diseases
CFDA Code
855
DUNS Number
605799469
UEI
HD1WMN6945W6
Project Start Date
01-August-2023
Project End Date
31-July-2028
Budget Start Date
01-August-2024
Budget End Date
31-July-2025
Project Funding Information for 2024
Total Funding
$69,428
Direct Costs
$44,648
Indirect Costs
$24,780
Year
Funding IC
FY Total Cost by IC
2024
National Institute of Allergy and Infectious Diseases
$69,428
Year
Funding IC
FY Total Cost by IC
Sub Projects
No Sub Projects information available for 3DP2AI171150-02S1
Publications
Publications are associated with projects, but cannot be identified with any particular year of the project or fiscal year of funding. This is due to the continuous and cumulative nature of knowledge generation across the life of a project and the sometimes long and variable publishing timeline. Similarly, for multi-component projects, publications are associated with the parent core project and not with individual sub-projects.
No Publications available for 3DP2AI171150-02S1
Patents
No Patents information available for 3DP2AI171150-02S1
Outcomes
The Project Outcomes shown here are displayed verbatim as submitted by the Principal Investigator (PI) for this award. Any opinions, findings, and conclusions or recommendations expressed are those of the PI and do not necessarily reflect the views of the National Institutes of Health. NIH has not endorsed the content below.
No Outcomes available for 3DP2AI171150-02S1
Clinical Studies
No Clinical Studies information available for 3DP2AI171150-02S1
News and More
Related News Releases
No news release information available for 3DP2AI171150-02S1
History
No Historical information available for 3DP2AI171150-02S1
Similar Projects
No Similar Projects information available for 3DP2AI171150-02S1